Metraipolis › archive › dc_dfd8c9022bfd

Duo biologic therapy using mepolizumab and omalizumab in refractory ABPA: two cases — Europe PMC PMID:40898293

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/40898293
DOI: 10.1186/s13223-[numero omesso]-0
License (as archived): solo-consultazione
Archived: 2026-11-10T04:49:04.619Z
SHA-256 of the archived text: 82d886409c2e287d2e054fd632d04d927328f43fe90666d0daa3e2b8524e5974
Stable URL of this page: https://metraipolis.com/documento/dc_dfd8c9022bfd

How to cite

Duo biologic therapy using mepolizumab and omalizumab in refractory ABPA: two cases — Europe PMC PMID:40898293 — Europe PMC (en), https://europepmc.org/article/MED/40898293 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_dfd8c9022bfd (Metraipolis archive dc_dfd8c9022bfd, sha256 82d886409c2e287d2e054fd632d04d927328f43fe90666d0daa3e2b8524e5974)

BibTeX

@misc{dcdfd8c9022bfd,
  title = {Duo biologic therapy using mepolizumab and omalizumab in refractory ABPA: two cases — Europe PMC PMID:40898293},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40898293},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_dfd8c9022bfd; sha256 82d886409c2e287d2e054fd632d04d927328f43fe90666d0daa3e2b8524e5974},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40898293. Agents can read the archived copy with the MCP tool read_document.